CN102504026A - 全人源的抗人表皮生长因子受体的单链抗体及其应用 - Google Patents
全人源的抗人表皮生长因子受体的单链抗体及其应用 Download PDFInfo
- Publication number
- CN102504026A CN102504026A CN2011103696209A CN201110369620A CN102504026A CN 102504026 A CN102504026 A CN 102504026A CN 2011103696209 A CN2011103696209 A CN 2011103696209A CN 201110369620 A CN201110369620 A CN 201110369620A CN 102504026 A CN102504026 A CN 102504026A
- Authority
- CN
- China
- Prior art keywords
- antibody
- factor receptor
- epidermal growth
- aminoacid sequence
- chain antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060006698 EGF receptor Proteins 0.000 title claims abstract description 27
- 102000001301 EGF receptor Human genes 0.000 title claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 27
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 25
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 25
- 229940116978 human epidermal growth factor Drugs 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 150000001413 amino acids Chemical group 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 238000001042 affinity chromatography Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 102000009465 Growth Factor Receptors Human genes 0.000 description 6
- 108010009202 Growth Factor Receptors Proteins 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 229960005395 cetuximab Drugs 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229910052759 nickel Inorganic materials 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- FIMHASWLGDDANN-UHFFFAOYSA-M methyl sulfate;tributyl(methyl)azanium Chemical compound COS([O-])(=O)=O.CCCC[N+](C)(CCCC)CCCC FIMHASWLGDDANN-UHFFFAOYSA-M 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000010023 transfer printing Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007299 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101100118548 Drosophila melanogaster Egfr gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102400001329 Epiregulin Human genes 0.000 description 1
- 101800000155 Epiregulin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110369620 CN102504026B (zh) | 2011-11-21 | 2011-11-21 | 全人源的抗人表皮生长因子受体的单链抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110369620 CN102504026B (zh) | 2011-11-21 | 2011-11-21 | 全人源的抗人表皮生长因子受体的单链抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102504026A true CN102504026A (zh) | 2012-06-20 |
CN102504026B CN102504026B (zh) | 2013-10-16 |
Family
ID=46216165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110369620 Active CN102504026B (zh) | 2011-11-21 | 2011-11-21 | 全人源的抗人表皮生长因子受体的单链抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102504026B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864935A (zh) * | 2014-03-06 | 2014-06-18 | 中国药科大学 | 一种靶向egfr/kdr特异性双链抗体 |
CN105601743A (zh) * | 2016-02-01 | 2016-05-25 | 苏州普罗达生物科技有限公司 | 一种抗vegfr2的单链抗体及其应用 |
CN106397594A (zh) * | 2016-10-25 | 2017-02-15 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1124501A (zh) * | 1994-03-17 | 1996-06-12 | 默克专利股份有限公司 | 抗表皮生长因子受体的单链可变区片段和抗体 |
CN1432063A (zh) * | 2000-05-19 | 2003-07-23 | 梨树化学株式会社 | 抗表皮生长因子受体的人源化抗体 |
CN1827647A (zh) * | 2005-03-02 | 2006-09-06 | 上海张江生物技术有限公司 | 重组抗egfr单克隆抗体 |
EP1885396A2 (en) * | 2005-05-04 | 2008-02-13 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
CN101233155A (zh) * | 2004-03-19 | 2008-07-30 | 伊姆克罗尼系统公司 | 人抗表皮生长因子受体抗体 |
-
2011
- 2011-11-21 CN CN 201110369620 patent/CN102504026B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1124501A (zh) * | 1994-03-17 | 1996-06-12 | 默克专利股份有限公司 | 抗表皮生长因子受体的单链可变区片段和抗体 |
CN1432063A (zh) * | 2000-05-19 | 2003-07-23 | 梨树化学株式会社 | 抗表皮生长因子受体的人源化抗体 |
CN101233155A (zh) * | 2004-03-19 | 2008-07-30 | 伊姆克罗尼系统公司 | 人抗表皮生长因子受体抗体 |
CN1827647A (zh) * | 2005-03-02 | 2006-09-06 | 上海张江生物技术有限公司 | 重组抗egfr单克隆抗体 |
EP1885396A2 (en) * | 2005-05-04 | 2008-02-13 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864935A (zh) * | 2014-03-06 | 2014-06-18 | 中国药科大学 | 一种靶向egfr/kdr特异性双链抗体 |
CN105601743A (zh) * | 2016-02-01 | 2016-05-25 | 苏州普罗达生物科技有限公司 | 一种抗vegfr2的单链抗体及其应用 |
CN106397594A (zh) * | 2016-10-25 | 2017-02-15 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
CN106397594B (zh) * | 2016-10-25 | 2019-06-04 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102504026B (zh) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11827697B2 (en) | Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof | |
WO2017201766A1 (zh) | 抗人pd-1人源化单克隆抗体及其应用 | |
CN109438576B (zh) | 一种抗人cd47单克隆抗体的制备及其应用 | |
CN102321173B (zh) | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 | |
CN108341884A (zh) | 基于IL-15和IL-15Rα SUSHI结构域的免疫细胞因子 | |
CN108373504A (zh) | Cd24特异性抗体和抗cd24-car-t细胞 | |
CN106397594B (zh) | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 | |
CN103068850A (zh) | 单链可变片段抗-cd133抗体及其用途 | |
SA109300723B1 (ar) | عملية لتضمين النشاط المضاد لجسم مضاد أحادي النسيلة | |
CN109776678A (zh) | 一种人源化pd-l1单克隆抗体、其制备方法和应用 | |
CN106432502A (zh) | 用于治疗cea阳性表达肿瘤的双特异纳米抗体 | |
CN101701039B (zh) | Fmu-epcam-2a9单克隆抗体的轻链和重链可变区 | |
CN110049998A (zh) | 针对程序性细胞死亡1(pd-1)的新抗体及其用途 | |
CN101863980A (zh) | 全人源抗血管内皮细胞生长因子受体2单链抗体 | |
CN102504026B (zh) | 全人源的抗人表皮生长因子受体的单链抗体及其应用 | |
CN104098698A (zh) | 一种抗cd3抗体及其制法和应用 | |
CN113402607B (zh) | 一种抗lap单克隆抗体、其抗原结合片段及其应用 | |
CN103649326A (zh) | 用于治疗和诊断用途的抗体样蛋白 | |
CN109071668A (zh) | 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体 | |
CN107964045A (zh) | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 | |
CN108290942A (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
CN106029094A (zh) | 新的抗adam17抗体及其用于治疗癌症的用途 | |
CN105504057B (zh) | 抗汉滩病毒鼠/人嵌合抗体及其应用 | |
CN105646712B (zh) | 单克隆抗体及其应用 | |
CN103601805B (zh) | 一种人fgf21单克隆抗体的轻链和重链可变区 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151211 Address after: 200233 Guiping Road, Xuhui District, No. 333, building 1, building 5, building Patentee after: CELLULAR BIOMEDICINE GROUP (SHANGHAI) Ltd. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231102 Address after: 201210 building 3, Faraday Road, China (Shanghai) free trade pilot area, Pudong New Area, Shanghai, China (3) Patentee after: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd. Address before: No. 5, building No. 1, No. 333, Guiping Road, Xuhui District, Shanghai Patentee before: CELLULAR BIOMEDICINE GROUP (SHANGHAI) Ltd. |